Development of a diagnostic method for severe cutaneous adverse reactions by genom biomarkers and their pathophysiological relevanceic

2017 Fiscal Year Final Research Report

• Project/Area Number: 26293122
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Applied pharmacology
• Research Institution: National Institute of Health Sciences
• Principal Investigator: Saito Yoshiro 国立医薬品食品衛生研究所, 医薬安全科学部, 部長 (50215571)
• Co-Investigator(Kenkyū-buntansha): 関根 章博 千葉大学, 予防医学センター, 教授 (30425631) ; 中村 亮介 国立医薬品食品衛生研究所, 医薬安全科学部, 室長 (50333357) ; 高橋 幸利 独立行政法人国立病院機構(静岡・てんかん神経医療センター臨床研究部), その他部局等, その他 (70262764) ; 相原 道子 横浜市立大学, 医学研究科, 教授 (90231753)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: ゲノム / バイオマーカー

Outline of Final Research Achievements

Lamotrigine, a drug for epileptics and bipolar disorder, is known to frequently cause severe cutaneous adverse reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN). We conducted HLA and genome-wide genetic polymorphism analysis of Japanese patients with SJS/TEN, and using the healthy adults' data as controls, we found plural significantly associated genetic polymorphisms even after correction of multiple comparison. The results should be validated using another set of patient/control samples. On the other hand, no significant HLA type has been found after the correction.

Free Research Field

医薬品安全性学